Aspira Women's Health (AWH) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 24, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	VERMILLION, INC.
Entity Central Index Key	926617
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Common Stock, Shares Outstanding		43,115,790
Entity Public Float			$50,201,743

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$22,965	$29,504
Accounts receivable	167	373
Prepaid expenses and other current assets	534	372
Total current assets	23,666	30,249
Property and equipment, net	508	391
Total assets	24,174	30,640
Current liabilities:
Accounts payable	1,123	541
Accrued liabilities	2,201	1,283
Short-term debt	1,106	1,106
Deferred revenue	489	628
Total current liabilities	4,919	3,558
Non-current liabilities:
Long-term deferred revenue		316
Total liabilities	4,919	3,874
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at December 31, 2014 and 2013
Common stock, $0.001 par value, 150,000,000 shares authorized; 43,115,790 and 35,825,673 shares issued and outstanding at December 31, 2014 and 2013, respectively	43	36
Additional paid-in capital	370,685	358,994
Accumulated deficit	-351,473	-332,264
Total stockholders' equity	19,255	26,766
Total liabilities and stockholders' equity	$24,174	$30,640

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	43,115,790	35,825,673
Common stock, shares outstanding	43,115,790	35,825,673

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Revenue:
Product	$2,067		$2,112
License	454		454
Total revenue	2,521		2,566
Cost of revenue:
Product	1,230		170
Gross profit	1,291		2,396
Operating expenses:
Research and development	4,667	[1]	2,595	[1]
Sales and marketing	9,893	[2]	4,480	[2]
General and administrative	5,942	[3]	4,184	[3]
Total operating expenses	20,502		11,259
Loss from operations	-19,211		-8,863
Interest income	40		23
Other income (expense), net	-38		21
Loss before income taxes	-19,209		-8,819
Income tax benefit (expense)
Net loss	-19,209		-8,819
Net loss per share-basic and diluted	($0.53)		($0.42)
Weighted average common shares used to compute basic and diluted net loss per common share	36,082,414		20,926,336
Net loss	($19,209)		($8,819)
[1]	Research and development $136, 76
[2]	Sales and marketing $259, 163
[3]	General and administrative $776, $637

Consolidated_Statements_Of_Ope1

Consolidated Statements Of Operations (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Research And Development [Member]
Stock-based compensation expense	$136	$76
Sales And Marketing [Member]
Stock-based compensation expense	259	163
General And Administrative [Member]
Stock-based compensation expense	$776	$637

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2012	$15,000	$328,097,000	($323,445,000)	$4,667,000
Beginning Balance (in shares) at Dec. 31, 2012	15,200,079
Net loss			-8,819,000	-8,819,000
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs (in shares)	8,000,000
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs	8,000	11,743,000		11,751,000
Warrant exercises, (in shares)	12,086,641
Warrant exercises	12,000	17,635,000		17,647,000
Common stock issued in conjuntion with exercise of stock options (in shares)	371,348			371,348
Common stock issued in conjuntion with execise of stock options	1,000	643,000		644,000
Common stock issued for restricted stock awards (in shares)	167,605
Common stock issued for restricted stock awards		361,000		361,000
Warrants issued for services		34,000		34,000
Stock compensation charge		481,000		481,000
Ending Balance at Dec. 31, 2013	36,000	358,994,000	-332,264,000	26,766,000
Ending Balance (in shares) at Dec. 31, 2013	35,825,673
Net loss			-19,209,000	-19,209,000
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs (in shares)	6,944,445
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs	7,000	10,281,000		10,288,000
Common stock offering - at-the-market (ATM), (in shares)	48,473
Common stock issued in conjuntion with exercise of stock options (in shares)	178,699			178,699
Common stock issued in conjuntion with execise of stock options		239,000		239,000
Common stock issued for restricted stock awards (in shares)	118,500
Common stock issued for restricted stock awards		351,000		351,000
Warrants issued for services		22,000		22,000
Stock compensation charge		798,000		798,000
Ending Balance at Dec. 31, 2014	$43,000	$370,685,000	($351,473,000)	$19,255,000
Ending Balance (in shares) at Dec. 31, 2014	43,115,790

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($19,209)	($8,819)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash license revenue	-454	-454
Depreciation and amortization	141	72
Stock-based compensation expense	1,149	842
Warrants issued for services	22	34
Changes in operating assets and liabilities:
Increase (decrease) in accounts receivable	206	-236
Increase in prepaid expenses and other current assets	-162	-24
Increase in accounts payable and accrued liabilities	1,500	225
(Decrease) increase in deferred revenue	-1	136
Net cash used in operating activities	-16,808	-8,224
Net Cash flows from investing activities:
Purchase of property and equipment	-258	-321
Cash flows from financing activities:
Proceeds from sale of common stock and warrants, net of issuance costs	10,288	11,751
Proceeds from exercise of common stock warrants		17,647
Proceeds from issuance of common stock from exercise of stock options	239	644
Net cash provided by financing activities	10,527	30,042
Net (decrease) increase in cash and cash equivalents	-6,539	21,497
Cash and cash equivalents, beginning of year	29,504	8,007
Cash and cash equivalents, end of year	$22,965	$29,504

Basis_Of_Presentation_And_Sign

Basis Of Presentation And Significant Accounting And Reporting Policies	12 Months Ended
	Dec. 31, 2014
Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Basis Of Presentation And Significant Accounting And Reporting Policies	NOTE 1:Basis of Presentation and Summary of Significant Accounting and Reporting Policies
	Organization
	Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease.  In March 2010, the Company commercially launched OVA1™ ovarian tumor triage test (“OVA1”). The Company distributes OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”), a related party (see Note 3) and through its wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc (“ASPiRA”), which opened on June 23, 2014.
	Liquidity
	On December 23, 2014, the Company completed a private placement pursuant to which certain investors purchased 6,944,445 shares of Vermillion common stock at a price of $1.44 per share. The Company also issued warrants to purchase shares of Vermillion common stock at a price of $0.125 per warrant share in the private placement. The proceeds of the private placement were $10,521,000 (net proceeds of approximately $10,281,000 after deducting offering expenses incurred through December 31, 2014). The warrants are exercisable, beginning on June 23, 2015, for 4,166,659 shares of Vermillion common stock at $2.00 per share and expire on December 23, 2017.
	The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of $351 million at December 31, 2014. The Company expects to incur a net loss in 2015 and the foreseeable future. The Company’s management believes that successful achievement of the business objectives will require additional financing.  The Company expects to raise capital through a variety of sources, which may include the public equity market, private equity financing, collaborative arrangements, licensing arrangements, and/or public or private debt. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition.
	There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations.  However, management believes that the current working capital position as of the date of these financial statements will be sufficient to meet the Company’s working capital needs for at least the next twelve months. Management expects cash from product sales to be the Company’s only material, recurring source of cash in 2015.
	Basis of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities.  Actual results could differ from those estimates.
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes.  Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper.  The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.
	Fair Value Measurement
	Accounting Standards Codification Topic 820 Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1 - Quoted prices in active markets for identical assets or liabilities.
	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable.  The Company maintains cash and cash equivalents in recognized financial institutions in the United States.  The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.
	Accounts receivable are derived from sales made to a customer located in North America.  The Company performs ongoing credit evaluations of its customer’s financial condition and generally does not require collateral.  The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable.  Accounts receivable at December 31, 2014 and 2013 and revenues for the years then ended are from one customer.
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations.
	Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable.  If property and equipment are considered to be impaired, an impairment loss is recognized.
	Revenue Recognition
	Product Revenue:  The Company derives product revenues from sales of OVA1 through Quest Diagnostics and ASPiRA.  Product revenues are recognized for tests performed when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.
	As the Company has not established sufficient payment history with the insurance companies or private payors for the tests performed at ASPiRA, payment is not fixed or determinable and collectability is not reasonably assured, and it will not recognize revenue until those criteria are met, which typically coincides with the collection of cash.  All costs incurred for tests performed at ASPiRA are expensed as incurred. Once the Company establishes a reliable payment history, it plans to return to normal accrual revenue recognition based on its criteria discussed above.
	License Revenue:  Under the terms of the secured line of credit with Quest Diagnostics, which was terminated on March 11, 2015, portions of the borrowed principal amounts were forgiven upon achievement of certain milestones relating to the development, regulatory approval and commercialization of certain diagnostic tests (see Note 3).  The Company accounts for forgiveness of principal debt balances as license revenues over the term of the exclusive sales period that Quest Diagnostics received upon commercialization of an approved diagnostic test as the Company does not have a sufficient history of product sales that provides a reasonable basis for estimating future product sales. License revenue is recognized on a straight-line basis over the original remaining period of Quest Diagnostics’ sales exclusivity ending in September 2015. The disputed exclusivity was formally terminated with Quest Diagnostics on March 11, 2015, and thus the remaining balance of deferred license revenue totaling $315,518 will be recognized as of that date.
	Research and Development Costs
	Research and development costs are expensed as incurred.  Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on the Company’s behalf. In addition, acquisitions of assets to be consumed in research and development are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.
	Patent Costs
	Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within selling, general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $380,000 and $475,000 for the years ended December 31, 2014 and 2013, respectively.
	Stock-Based Compensation
	The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model which requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment.
	The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding.  This data includes employees’ expected exercise and post-vesting employment termination behaviors.  The expected stock price volatility is estimated using a combination of historical and peer group volatility for a blended volatility in deriving the expected volatility assumption.  The Company made an assessment that blended volatility is more representative of future stock price trends than just using historical or peer group volatility, which corresponds to the expected life of the options.  The expected dividend yield is based on the estimated annual dividends that is expected to be paid over the expected life of the options as a percentage of the market value of Vermillion common stock as of the grant date.  The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date.  The Company uses the straight-line method to amortize the fair value over the vesting period of the award.
	The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options are recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another.
	Contingencies
	The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Managements believes that accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
	Income Taxes
	The Company accounts for income taxes using the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
	ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.
	The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.
	Net Loss Per Share
	Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period.  Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
	Fair Value of Financial Instruments
	Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments.
	Segment Reporting
	The Company operates one reportable segment.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2014
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	NOTE 2:Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2014-15, “Presentation of Financial Statements – Going Concern,” (ASU 2014-15).  ASU 2014-15 provides guidance with regard to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures.   ASU 2014-15clarified that management should perform its evaluation whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.  The accounting standard is effective for annual periods ending after December 15, 2016 and interim periods thereafter. Early adoption is permitted. Upon adoption management will evaluate the Company’s ability to continue as a going concern based on this guidance.
	In June 2014, the FASB issued ASU No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” (ASU 2014-12). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in ASU 2014-12 are effective for annual periods and interim periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of this standard is not expected to have a material effect on the Company’s financial statements.
	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” (ASU 2014-09), which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The accounting standard is effective for annual and interim periods beginning after December 15, 2016, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption. Early adoption is not permitted. The Company is currently evaluating the impact and the method of adopting this standard.

Strategic_Alliance_And_Secured

Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	12 Months Ended
	Dec. 31, 2014
Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated [Abstract]
Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	NOTE 3:Strategic Alliance And Secured Line Of Credit with Quest Diagnostics Incorporated
	Quest Diagnostics is a holder of the Company’s common stock. In July 2005, the Company entered into a Strategic Alliance Agreement (as amended, the “Strategic Alliance Agreement”) with Quest Diagnostics to develop and commercialize up to three diagnostic tests from the Company’s product pipeline.  In connection with the Strategic Alliance Agreement, the Company entered into a credit agreement with Quest Diagnostics, pursuant to which Quest Diagnostics provided the Company with a $10,000,000 secured line of credit to be used to pay for certain costs and expenses related to activities under the Strategic Alliance Agreement. This line of credit was collateralized by certain of the Company’s intellectual property assets. Pursuant to the Strategic Alliance Agreement, Quest Diagnostics selected two diagnostic tests to be commercialized, a peripheral arterial disease diagnostic test (differentiated from the Company’s legacy program) and OVA1. The credit agreement provided for the forgiveness of portions of the amounts borrowed under the secured line of credit upon the achievement of certain milestones related to the development, regulatory approval and commercialization of certain diagnostic tests. If not otherwise forgiven, the $10,000,000 principal amount outstanding under this secured line of credit became due and payable on October 7, 2012. Through December 31, 2013, a total of $3,000,000 was acknowledged as forgiven by Quest Diagnostics based upon milestone achievement.
	The Company believed that in September 2009 when the United States Food and Drug Administration (the “FDA”) cleared its application for a licensed laboratory test of OVA1 to be commercialized, the Company achieved a milestone under the credit agreement, resulting in a $1,000,000 reduction of the outstanding principal amount borrowed under the credit agreement.  However, Quest Diagnostics disputed whether this milestone had been achieved.
	The dispute regarding the balance of the loan was resolved on March 11, 2015 for a payment to Quest Diagnostics totaling $1,069,000.
	Unrelated to the debt dispute described above, on May 23, 2013, the Company sent Quest Diagnostics a notice of default under the Strategic Alliance Agreement relating to a number of its material violations, breaches and failures to perform under the Strategic Alliance Agreement. The Strategic Alliance Agreement stated that if a party failed to cure material defaults within 90 days of the date of the notice of default, the other party had the right to terminate the Strategic Alliance Agreement.  Quest Diagnostics disputed the effectiveness of the Company’s notice of default. On August 23, 2013, the Company sent Quest Diagnostics a notice of termination. Notwithstanding the termination, the Company agreed that Quest Diagnostics could continue to make OVA1 available to healthcare providers on the same financial terms following the termination while negotiating in good faith towards an alternative business structure. Prior to the termination, Quest Diagnostics had the non-exclusive right to commercialize OVA1 on a worldwide basis, with exclusive commercialization rights in the clinical reference laboratory marketplace in the United States, India, Mexico, and the United Kingdom through September 2014, with the right to extend the exclusivity period for one additional year. As a result of ongoing negotiations, on March 11, 2015, we reached a settlement agreement with Quest Diagnostics that terminated all disputes related to our prior strategic alliance and loan agreements.  We also entered into a new commercial agreement with Quest Diagnostics.  Pursuant to this agreement, Vermillion’s wholly-owned subsidiary, ASPiRA LABS, will begin to offer OVA1 testing to Quest Diagnostics customers. We expect Quest Diagnostics to transfer all OVA1 U.S. testing services to ASPiRA LABS, starting with 39 states this year, while continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing for a period of two years from the date of the agreement. Pursuant to the agreement, Quest Diagnostics will also continue to offer OVA1 services through its own labs in the remaining 11 states, until ASPiRA LABS has obtained the state approvals required to provide those services.  Quest will receive a fee for collection and logistic support services it provides.  Per the terms of the agreement, we will not offer to existing or future Quest Diagnostics customers CA 125-II or other tests that Quest Diagnostics offers.
	Accounts receivable from Quest Diagnostics totaled $167,000 and $373,000 at December 31, 2014 and 2013, respectively.

Property_And_Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2014
Property And Equipment [Abstract]
Property And Equipment	Note 4:       Property and Equipment
	The components of property and equipment as of December 31, 2014 and 2013 were as follows:
		December 31,
	(in thousands)		2014		2013
	Machinery and equipment	$	563	$	501
	Demonstration equipment		38		33
	Computer equipment and software		291		116
	Furniture and fixtures		68		75
	Gross property and equipment		960		725
	Accumulated depreciation and amortization		-452		-334
	Property and equipment, net	$	508	$	391
	Depreciation expense for property and equipment was $141,000 and $72,000 for the years ended December 31, 2014 and 2013, respectively.

Accured_Liabilities

Accured Liabilities	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities [Abstract]
Accrued Liabilities	NOTE 5:Accrued Liabilities
	The components of accrued liabilities as of December 31, 2014 and 2013 were as follows:
		December 31,
	(in thousands)	2014		2013
	Payroll and benefits related expenses	$	905	$	548
	Collaboration and research agreements expenses		338		187
	Professional services		598		262
	Tax-related liabilities		23		42
	Other accrued liabilities		337		244
	Total accrued liabilities	$	2,201	$	1,283

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies [Abstract]
Commitments And Contingencies	NOTE 6:Commitments and Contingencies
	Operating Leases
	The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease.  Vermillion leases its principal facility and CLIA laboratory located near Austin, Texas. The leases include an annual base rent of $130,000 and annual estimated common area charges, taxes and insurance of $62,000 and expire at various times prior to May 31, 2016.
	Rental expense under operating leases for the years ended December 31, 2014 and 2013 totaled $130,000 and $96,000, respectively.
	Noncancelable Collaboration Obligations and Other Commitments
	Vermillion has a research collaboration agreement with The Johns Hopkins University School of Medicine (“JHU”) directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human disease through March 2016.  At December 31, 2014, Vermillion was obligated to pay JHU $625,000 in collaboration support through the expiration of the agreement in March 2016. Collaboration expenses under the JHU collaboration were $1,323,000 and $658,000 for the years ended December 31, 2014 and 2013, respectively.  Collaboration expenses under the JHU collaboration are included in research and development expenses.  In addition, under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500.
	Contingent Liabilities
	From time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations.  The Company establishes reserves for specific liabilities in connection with legal actions that management deems to be probable and estimable.  Other than as disclosed above, the Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Common_Stock

Common Stock	12 Months Ended
	Dec. 31, 2014
Common Stock [Abstract]
Common Stock
	NOTE 7:Common Stock
	2014 Private Placement Sale
	On December 23, 2014, the Company completed a private placement pursuant to which certain investors purchased 6,944,445 shares of Vermillion common stock at a price of $1.44 per share. The Company also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. The proceeds of the private placement were $10,521,000 (net proceeds of approximately $10,281,000 after deducting offering expenses). The warrants are exercisable, beginning on June 23, 2015, for 4,166,659 shares of Vermillion common stock at $2.00 per share and expire on December 23, 2017.
	The purchase of common stock and warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is $2,970,000 and for the common stock is $7,311,000.
	Other 2014 Equity Offerings
	In October 2014, the Company established an at-the-market offering program, pursuant to which it may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $15.0 million. The Company is obligated to pay a commission of up to 3.0% of the gross proceeds from the sale of shares of Vermillion common stock in the offering. The Company is not obligated to sell any shares of Vermillion common stock in the offering. During the year ended December 31, 2014, approximately 48,473 shares of the Vermillion common stock were sold under the program for aggregate proceeds of $75,000  (no net proceeds after deducting offering costs). The Company suspended the program on December 24, 2014.
	2013 Private Placement Sale
	On May 13, 2013, the Company completed a private placement pursuant to which existing and new investors purchased 8,000,000 shares of Vermillion common stock at a price of $1.46 per share. In the private placement, Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share. The proceeds of the private placement were $13,242,500 (net proceeds of approximately $11,751,000 after deducting offering expenses). The warrants were exercisable for 12,500,000 shares of common stock at $1.46 per share and expire on May 13, 2016. On December 19, 2013, certain holders exercised warrants to purchase 12,087,000 common shares for net proceeds of $17,647,000.
	The purchase of common stock and warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid in capital. The value ascribed to the warrants is $9,300,000 and for the common stock is $3,943,000.
	In connection with the 2013 private placement, Vermillion entered into a stockholders agreement with the purchasers named in that agreement. Pursuant to and subject to the terms of the stockholders agreement, certain of the investors received rights to participate in any future equity offerings on the same price and terms as other investors.  In addition, the stockholders agreement prohibits the Company from taking material actions without the consent of at least one of the two primary investors.  These material actions include:
		Making any acquisition with value greater than $2 million;
		Entering into, or amending the terms of agreements with Quest Diagnostics, provided that such investors’ consent shall not be unreasonably withheld, conditioned or delayed following good faith consultation with the Company;
		Submitting any resolution at a meeting of stockholders or in any other manner changing or authorizing a change in the size of the Board of Directors;
		Offering, selling or issuing any securities senior to Vermillion’s common stock or any securities that are convertible into or exchangeable or exercisable for securities ranking senior to Vermillion’s common stock;
		Amending Vermillion’s certificate of incorporation or by-laws in any manner that affects the rights, privileges or economics of Vermillion common stock or the warrants described above;
		Taking any action that would result in a change in control of Vermillion or an insolvency event;
		Paying or declaring dividends on any securities of the Company or distributing any assets of the Company other than in the ordinary course of business or repurchasing any outstanding securities of the Company; or
		Adopting or amending any shareholder rights plan.
	In addition, the two primary investors each received the right to designate a person to serve on Vermillion’s Board of Directors. These rights terminate for each stockholder when that stockholder ceases to beneficially own less than 50% of the shares and warrants (taking into account shares issued upon exercise of the warrants), in the aggregate, than were purchased at the closing of the private placement.
	Warrants
	Warrants outstanding as of December 31, 2014 and 2013 were as follows:
			Exercise Price	Number of Shares Outstanding under Warrant
	Issuance Date	Expiration Date	per Share	31-Dec-14	31-Dec-13
	1-May-12	30-Apr-14	$             3.18	-	21,000
	1-Nov-12	31-Oct-14	$             1.93	-	21,000
	1-May-13	30-Apr-15	$             1.88	21,000	21,000
	13-May-13	13-May-16	$             1.46	413,359	413,359
	1-Nov-13	31-Oct-15	$             3.89	21,000	21,000
	1-May-14	30-Apr-16	$             4.70	7,000	-
	23-Dec-14	23-Dec-17	$             2.00	4,166,659	-
				4,629,018	497,359

Loss_Per_Share

Loss Per Share	12 Months Ended
	Dec. 31, 2014
Loss Per Share [Abstract]
Loss Per Share
	NOTE 8:Loss Per Share
	The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December 31, 2014 and 2013 was as follows:
		Loss			Shares	Per Share
	(In thousands, except per share data)	(Numerator)			(Denominator)	Amount
	Year ended December 31, 2013:
	Net loss - basic	$	-8,819		20,926,336	$	-0.42
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards		-		-
	Net loss - diluted	$	-8,819		20,926,336	$	-0.42
	Year ended December 31, 2014:
	Net loss - basic	$	-19,209		36,082,414	$	-0.53
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards		-		-
	Net loss - diluted	$	-19,209		36,082,414	$	-0.53
	Due to net losses for the years ended December 31, 2014 and 2013, diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential shares of common stock  that are antidilutive.
	The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December 31, 2014 and 2013 were as follows:
		Year Ended December 31,
		2014		2013
	Stock options	1,711,046		1,447,968
	Stock warrants	4,629,018		497,359
	Restricted stock units	-		1,667
	Potential common shares	6,340,064		1,946,994

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Employee Benefit Plans [Abstract]
Employee Benefit Plans	NOTE 9:Employee Benefit Plans
	2000 Stock Plan
	Under the Amended and Restated 2000 Stock Plan (the “2000 Plan”), options could be granted at prices not lower than 85% and 100% of the fair market value of the common stock for non-statutory and statutory stock options, respectively.  Options generally vest monthly over a period of four years and unexercised options generally expire ten years from the date of grant.  The authority of Vermillion’s Board of Directors to grant new stock options and awards under the 2000 Plan terminated in 2010.  Options to purchase 15,000 and 125,000 shares of common stock were exercised during the years ended December 31, 2014 and 2013, respectively. As of December 31, 2013, options to purchase 57,900 shares of common stock remained outstanding under the 2000 Plan.  No additional shares of common stock were reserved for future option grants under the 2000 Plan.
	2010 Stock Incentive Plan
	Under the 2010 Plan, employees, directors and consultants of the Company are eligible to receive awards. The 2010 Plan is administered by the Compensation Committee of the Vermillion Board of Directors. The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan originally provided for issuance of up to 1,322,983 shares of Vermillion common stock, subject to adjustment as provided in the 2010 Plan. On December 12, 2013, the Company’s stockholders approved an increase of 2,300,000 in the number of shares available for issuance under the 2010 Plan for a total of 3,622,983 shares. Unexercised options generally expire ten years from the date of grant. Options to purchase 163,490 and 246,348 shares of common stock were exercised during the year ended December 31, 2014 and 2013, respectively.
	During the year ended December 31, 2014, the Company issued to the Vermillion Board of Directors 103,500 shares of restricted stock from the 2010 Plan having a fair value of $320,000 as payment for services rendered in 2014. During the year ended December 31, 2013, the Company issued to the Vermillion Board of Directors 160,938 shares of restricted stock from the 2010 Plan having a fair value of $334,000 as payment for services rendered in 2013.
	The activity related to shares available for grant under the 2000 Plan and the 2010 Plan for the years ended December 31, 2014 and 2013 was as follows:
		2000 Stock Plan		2010 Stock Option Plan		Total
	Shares available at December 31, 2012	-		22,471		22,471
	Additional shares reserved	-		2,300,000		2,300,000
	Options canceled	14,150		68,908		83,058
	Reduction in shares reserved	-14,150		-		-14,150
	Options granted	-		-810,000		-810,000
	Restricted stock units granted	-		-160,938		-160,938
	Shares available at December 31, 2013	-		1,420,441		1,420,441
	Options canceled	124,397		945,826		1,070,223
	Reduction in shares reserved	-124,397		-		-124,397
	Options granted	-		-1,512,000		-1,512,000
	Restricted stock units granted	-		-128,500		-128,500
	Restricted stock units canceled	-		11,667		11,667
	Shares available at December 31, 2014	-		737,434		737,434
	The stock option activity under the 2000 Plan and 2010 Plan for the years ended December 31, 2014 and 2013 was as follows:
		Number of Shares		Weighted Average Exercise Price			Aggregate Intrinsic Value			Weighted Average Remaining Contractual  Term
	Options outstanding at December 31, 2012	1,092,374		$	4.17		$	20		6.23
	Granted	810,000			2.05
	Exercised	-371,348			1.63
	Canceled	-83,058			8.66
	Options outstanding at December 31, 2013	1,447,968		$	3.36		$	780		7.94
	Granted	1,512,000			2.58
	Exercised	-178,699			1.34
	Canceled	-1,070,223			3.77
	Options outstanding at December 31, 2014	1,711,046		$	2.62		$	178		7.82
	Shares exercisable:
	31-Dec-14	729,094		$	2.95		$	72		5.78
	Shares expected to vest:
	31-Dec-14	805,201		$	2.38		$	106		9.34
	The range of exercise prices for options outstanding and exercisable at December 31, 2014 is as follows:
		Exercise Price					Options Outstanding			Weighted  Average Exercise Price	Weighted Average  Remaining Life in Years	Options Exercisable		Weighted Average Exercise Price
	$	0.01	-	$	1.3		42,500		$	1.3	9.95	-	$	-
		1.31	-		2.12		713,083			1.8	6.77	413,025		1.84
		2.13	-		3.09		724,874			2.7	8.83	203,923		2.95
		3.1	-		9.92		208,003			3.5	8.16	89,560		3.66
		9.93	-		28.65		22,586			20.28	1.43	22,586		20.28
	$	0.01	-	$	28.65		1,711,046		$	2.62	7.82	729,094	$	2.95
	(in thousands)		Total Intrinsic Value of Options Exercised			Total Fair Value of Vested Options
	Year ended December 31, 2014	$	55		$	655
	Year ended December 31, 2013	$	291		$	550
	Stock-based Compensation
	Employee Stock-based Compensation Expense
	The assumptions used to calculate the fair value of options granted under the 2010 Plan that were incorporated in the Black-Scholes pricing model for the years ended December 31, 2014 and 2013 were as follows:
		Year Ended December 31,
		2014				2013
	Dividend yield		-	%			-	%
	Volatility		80	%			79	%
	Risk-free interest rate		1.92	%			1.91	%
	Expected lives (years)		6.0				6.0
	Weighted average fair value	$	1.78			$	1.50
	The allocation of stock-based compensation expense by functional area for the years ended December 31, 2014 and 2013 was as follows:
		Year Ended December 31,
	(in thousands)		2014			2013
	Research and development	$	136		$	74
	Sales and marketing		259			163
	General and administrative		742			602
	Total	$	1,137		$	839
As of December 31, 2014, total unrecognized compensation cost related to nonvested stock option awards was approximately $1,371,000 and the related weighted average period over which it is expected to be recognized was 3.03 years.
401(k)Plan
The Company’s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0% of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit.  The Company is not required to make contributions under the 401(k) Plan.  During the years ended December 31, 2014 and 2013, the Company did not contribute to the 401(k) Plan.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Income Taxes	NOTE 10:Income Taxes
	For the years ended December 31, 2014 and 2013 the entire net loss was generated from domestic operations.
	Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets will not be fully realizable due to the history of the Company’s operating losses.  Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets at December 31, 2014 and 2013. There was no income tax expense or benefit for the years ended December 31, 2014 or 2013.
	The components of deferred tax assets (liabilities) at December 31, 2014 and 2013 were as follows:
		Year Ended December 31,
	(in thousands)	2014			2013
	Deferred tax assets:
	Depreciation and amortization	$	7,805		$	8,698
	Other		1,358			1,651
	Net operating losses		58,276			54,005
	Total deferred tax assets		67,439			64,354
	Valuation allowance		-67,431			-64,346
	Net deferred tax assets	$	8		$	8
	Deferred tax liabilities:
	Other	$	-8		$	-8
	Total deferred tax liabilities	$	-8		$	-8
	Net deferred tax asset (liability)	$	-		$	-
	The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2014 and 2013 was as follows:
		Year Ended December 31,
		2014			2013
	Tax at federal statutory rate	34	%		34	%
	State tax, net of federal benefit	1			2
	Valuation allowance	-16			-39
	Change in warrant valuation	-			-
	Net operating loss and credit reduction due to section 382 limitations	-			-
	Permanent items	-3			-1
	Other	-16			4
	Effective income tax rate	-	%		-	%
	As of December 31, 2014, the Company had a net operating loss of approximately $165,000,000 for federal and $140,000,000 for state tax purposes.  If not utilized, these carryforwards will begin to expire beginning in 2025 for federal purposes and 2016 for state purposes. In 2016, approximately $5,000,000 of the Company’s state net operating loss will expire. As of December 31, 2013, the Company had a net operating loss of approximately $146,000,000 for federal and $121,000,000 for state tax purposes.
	The Company’s ability to use net operating loss credit carryforwards may be restricted due to ownership change limitations occurring in the past or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986 (“Section 382”), as amended, as well as similar state provisions. These ownership changes may also limit the amount of net operating loss credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively.
	The Company believes that Section 382 ownership changes occurred as a result of the follow-on public common stock offering in 2011 and 2013. Any limitation may result in the expiration of a portion of the net operating loss credit carryforwards before utilization and any net operating loss credit carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. Due to the existence of a valuation allowance, it is not expected that such limitations, if any, will have an impact on the results of operations or financial position.
	The valuation allowance was $70,000,000 and $64,000,000 at December 31, 2014 and 2013, respectively. The increase of $6,000,000 between 2014 and 2013 is primarily due to adjustments to the domestic deferred tax assets related net operating losses.
	The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2014, the Company’s federal returns for the years ended 2011 through the current period and most state returns for the years ended 2010 through the current period are still open to examination. In addition, all of the net operating losses and research and development credits generated in years earlier than 2011 and 2010, respectively, are still subject to Internal Revenue Service audit. The federal and California tax returns for the year ended December 31, 2013 reflect research and development carryforwards of $5,040,000 and $5,024,000, respectively. The Company has recognized additional deferred tax assets for federal and California research and development credits of $148,000 and $111,000 for the year ended December 31, 2014, respectively.  As of December 31, 2014, the Company’s gross unrecognized tax benefits are approximately $10,322,000 which are attributable to research and development credits.  A reconciliation of the change in the Company’s unrecognized tax benefits is as follows:
	(in thousands)			Federal Tax			State Tax		Total
	Balance at December 31, 2012		$	5,655		$	5,242	$	10,897
	Increase in tax position during 2012			72			54		126
	Decrease due to expirations			-687			-272		-959
	Balance at December 31, 2013		$	5,040		$	5,024	$	10,064
	Increase in tax position during 2014			148			111		259
	Decrease due to expirations			-			-		-
	Balance at December 31, 2014		$	5,188		$	5,135	$	10,323
	The increase for the year ended December 31, 2014 relates to a tax position taken during the current year. The increase for the year ended December 31, 2013 is related to tax positions taken during 2013 and prior years. If the unrecognized income tax benefit is recognized, all of it would impact the effective tax rate in the period in which each of the benefits is recognized.
	The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations. The Company has not recorded any interest or penalties as a result of uncertain tax positions as of December 31, 2014 and 2013. Accrued interest and penalties would be included within the related liability in the consolidated balance sheet.

Other_Related_Party_Transactio

Other Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Other Related Party Transactions [Abstract]
Other Related Party Transactions	NOTE 11:Other Related Party Transactions
	On October 23, 2014, the Company appointed Valerie Palmieri as Chief Operating Officer (“COO”). Vermillion was party to a consulting agreement with a company owned by the COO to provide laboratory operations and commercialization consulting services to Vermillion.  The Company made payments of $340,000 for services provided pursuant to the consulting agreement through September 30, 2014. The consulting agreement was terminated as of October 23, 2014. In connection with the work performed under the consulting agreement, the Company granted Ms. Palmieri 15,000 shares of restricted stock under the 2010 Plan having a fair value of approximately $31,000 for achievement of certain milestones. Ms. Palmieri was named President and Chief Executive Officer effective January 1, 2015.
	On October 10, 2014, the Company entered into a consulting agreement with David Schreiber, a member of Vermillion’s Board of Directors.  Pursuant to the terms of the consulting agreement, Mr. Schreiber provided consulting services regarding finance and corporate strategy and was paid $375 per hour.  For the year ended December 31, 2014, the total amount of consulting fee expense for Mr. Schreiber was $22,375.

Basis_Of_Presentation_And_Sign1

Basis Of Presentation And Significant Accounting And Reporting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization	Organization
	Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease.  In March 2010, the Company commercially launched OVA1™ ovarian tumor triage test (“OVA1”). The Company distributes OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”), a related party (see Note 3) and through its wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc (“ASPiRA”), which opened on June 23, 2014.
Liquidity	Liquidity
	On December 23, 2014, the Company completed a private placement pursuant to which certain investors purchased 6,944,445 shares of Vermillion common stock at a price of $1.44 per share. The Company also issued warrants to purchase shares of Vermillion common stock at a price of $0.125 per warrant share in the private placement. The proceeds of the private placement were $10,521,000 (net proceeds of approximately $10,281,000 after deducting offering expenses incurred through December 31, 2014). The warrants are exercisable, beginning on June 23, 2015, for 4,166,659 shares of Vermillion common stock at $2.00 per share and expire on December 23, 2017.
	The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of $351 million at December 31, 2014. The Company expects to incur a net loss in 2015 and the foreseeable future. The Company’s management believes that successful achievement of the business objectives will require additional financing.  The Company expects to raise capital through a variety of sources, which may include the public equity market, private equity financing, collaborative arrangements, licensing arrangements, and/or public or private debt. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition.
	There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations.  However, management believes that the current working capital position as of the date of these financial statements will be sufficient to meet the Company’s working capital needs for at least the next twelve months. Management expects cash from product sales to be the Company’s only material, recurring source of cash in 2015.
Basis Of Consolidation	Basis of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions have been eliminated in consolidation
Use Of Estimates	Use of Estimates
	The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities.  Actual results could differ from those estimates.
Cash And Cash Equivalents	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes.  Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper.  The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.
Fair Value Measurement	Fair Value Measurement
	Accounting Standards Codification Topic 820 Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1 - Quoted prices in active markets for identical assets or liabilities.
	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
Concentration Of Credit Risk	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable.  The Company maintains cash and cash equivalents in recognized financial institutions in the United States.  The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.
	Accounts receivable are derived from sales made to a customer located in North America.  The Company performs ongoing credit evaluations of its customer’s financial condition and generally does not require collateral.  The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable.  Accounts receivable at December 31, 2014 and 2013 and revenues for the years then ended are from one customer.
Property And Equipment	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations.
	Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable.  If property and equipment are considered to be impaired, an impairment loss is recognized.
Revenue Recognition	Revenue Recognition
	Product Revenue:  The Company derives product revenues from sales of OVA1 through Quest Diagnostics and ASPiRA.  Product revenues are recognized for tests performed when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.
	As the Company has not established sufficient payment history with the insurance companies or private payors for the tests performed at ASPiRA, payment is not fixed or determinable and collectability is not reasonably assured, and it will not recognize revenue until those criteria are met, which typically coincides with the collection of cash.  All costs incurred for tests performed at ASPiRA are expensed as incurred. Once the Company establishes a reliable payment history, it plans to return to normal accrual revenue recognition based on its criteria discussed above.
	License Revenue:  Under the terms of the secured line of credit with Quest Diagnostics, which was terminated on March 11, 2015, portions of the borrowed principal amounts were forgiven upon achievement of certain milestones relating to the development, regulatory approval and commercialization of certain diagnostic tests (see Note 3).  The Company accounts for forgiveness of principal debt balances as license revenues over the term of the exclusive sales period that Quest Diagnostics received upon commercialization of an approved diagnostic test as the Company does not have a sufficient history of product sales that provides a reasonable basis for estimating future product sales. License revenue is recognized on a straight-line basis over the original remaining period of Quest Diagnostics’ sales exclusivity ending in September 2015. The disputed exclusivity was formally terminated with Quest Diagnostics on March 11, 2015, and thus the remaining balance of deferred license revenue totaling $315,518 will be recognized as of that date.
Research And Development Costs	Research and Development Costs
	Research and development costs are expensed as incurred.  Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on the Company’s behalf. In addition, acquisitions of assets to be consumed in research and development are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.
Patent Costs	Patent Costs
	Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within selling, general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $380,000 and $475,000 for the years ended December 31, 2014 and 2013, respectively.
Stock-Based Compensation	Stock-Based Compensation
	The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model which requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment.
	The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding.  This data includes employees’ expected exercise and post-vesting employment termination behaviors.  The expected stock price volatility is estimated using a combination of historical and peer group volatility for a blended volatility in deriving the expected volatility assumption.  The Company made an assessment that blended volatility is more representative of future stock price trends than just using historical or peer group volatility, which corresponds to the expected life of the options.  The expected dividend yield is based on the estimated annual dividends that is expected to be paid over the expected life of the options as a percentage of the market value of Vermillion common stock as of the grant date.  The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date.  The Company uses the straight-line method to amortize the fair value over the vesting period of the award.
	The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options are recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another.
Contingencies	Contingencies
	The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Managements believes that accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
Income Taxes	Income Taxes
	The Company accounts for income taxes using the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
	ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.
	The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.
Net Loss Per Share	Net Loss Per Share
	Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period.  Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments
	Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments.
Segment Reporting	Segment Reporting
	The Company operates one reportable segment.

Property_And_Equipment_Tables

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property And Equipment [Abstract]
Components Of Property And Equipment
		December 31,
	(in thousands)		2014		2013
	Machinery and equipment	$	563	$	501
	Demonstration equipment		38		33
	Computer equipment and software		291		116
	Furniture and fixtures		68		75
	Gross property and equipment		960		725
	Accumulated depreciation and amortization		-452		-334
	Property and equipment, net	$	508	$	391

Accurued_Liabilities_Tables

Accurued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities [Abstract]
Components Of Accrued Liabilities
		December 31,
	(in thousands)	2014		2013
	Payroll and benefits related expenses	$	905	$	548
	Collaboration and research agreements expenses		338		187
	Professional services		598		262
	Tax-related liabilities		23		42
	Other accrued liabilities		337		244
	Total accrued liabilities	$	2,201	$	1,283

Common_Stock_Tables

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Common Stock [Abstract]
Schedule Of Warrants Outstanding
			Exercise Price	Number of Shares Outstanding under Warrant
	Issuance Date	Expiration Date	per Share	31-Dec-14	31-Dec-13
	1-May-12	30-Apr-14	$             3.18	-	21,000
	1-Nov-12	31-Oct-14	$             1.93	-	21,000
	1-May-13	30-Apr-15	$             1.88	21,000	21,000
	13-May-13	13-May-16	$             1.46	413,359	413,359
	1-Nov-13	31-Oct-15	$             3.89	21,000	21,000
	1-May-14	30-Apr-16	$             4.70	7,000	-
	23-Dec-14	23-Dec-17	$             2.00	4,166,659	-
				4,629,018	497,359

Loss_Per_Share_Tables

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Loss Per Share [Abstract]
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share
		Loss			Shares	Per Share
	(In thousands, except per share data)	(Numerator)			(Denominator)	Amount
	Year ended December 31, 2013:
	Net loss - basic	$	-8,819		20,926,336	$	-0.42
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards		-		-
	Net loss - diluted	$	-8,819		20,926,336	$	-0.42
	Year ended December 31, 2014:
	Net loss - basic	$	-19,209		36,082,414	$	-0.53
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards		-		-
	Net loss - diluted	$	-19,209		36,082,414	$	-0.53
Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation
		Year Ended December 31,
		2014		2013
	Stock options	1,711,046		1,447,968
	Stock warrants	4,629,018		497,359
	Restricted stock units	-		1,667
	Potential common shares	6,340,064		1,946,994

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2014
Employee Benefit Plans [Abstract]
Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan
		2000 Stock Plan		2010 Stock Option Plan		Total
	Shares available at December 31, 2012	-		22,471		22,471
	Additional shares reserved	-		2,300,000		2,300,000
	Options canceled	14,150		68,908		83,058
	Reduction in shares reserved	-14,150		-		-14,150
	Options granted	-		-810,000		-810,000
	Restricted stock units granted	-		-160,938		-160,938
	Shares available at December 31, 2013	-		1,420,441		1,420,441
	Options canceled	124,397		945,826		1,070,223
	Reduction in shares reserved	-124,397		-		-124,397
	Options granted	-		-1,512,000		-1,512,000
	Restricted stock units granted	-		-128,500		-128,500
	Restricted stock units canceled	-		11,667		11,667
	Shares available at December 31, 2014	-		737,434		737,434
Stock Option Activity Under 2000 Plan and 2010 Plan
		Number of Shares		Weighted Average Exercise Price			Aggregate Intrinsic Value			Weighted Average Remaining Contractual  Term
	Options outstanding at December 31, 2012	1,092,374		$	4.17		$	20		6.23
	Granted	810,000			2.05
	Exercised	-371,348			1.63
	Canceled	-83,058			8.66
	Options outstanding at December 31, 2013	1,447,968		$	3.36		$	780		7.94
	Granted	1,512,000			2.58
	Exercised	-178,699			1.34
	Canceled	-1,070,223			3.77
	Options outstanding at December 31, 2014	1,711,046		$	2.62		$	178		7.82
	Shares exercisable:
	31-Dec-14	729,094		$	2.95		$	72		5.78
	Shares expected to vest:
	31-Dec-14	805,201		$	2.38		$	106		9.34
Range of Exercise Prices for Options Outstanding and Exercisable
		Exercise Price					Options Outstanding			Weighted  Average Exercise Price	Weighted Average  Remaining Life in Years	Options Exercisable		Weighted Average Exercise Price
	$	0.01	-	$	1.3		42,500		$	1.3	9.95	-	$	-
		1.31	-		2.12		713,083			1.8	6.77	413,025		1.84
		2.13	-		3.09		724,874			2.7	8.83	203,923		2.95
		3.1	-		9.92		208,003			3.5	8.16	89,560		3.66
		9.93	-		28.65		22,586			20.28	1.43	22,586		20.28
	$	0.01	-	$	28.65		1,711,046		$	2.62	7.82	729,094	$	2.95
Fair Value of Options Vested
	(in thousands)		Total Intrinsic Value of Options Exercised			Total Fair Value of Vested Options
	Year ended December 31, 2014	$	55		$	655
	Year ended December 31, 2013	$	291		$	550
Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan
		Year Ended December 31,
		2014				2013
	Dividend yield		-	%			-	%
	Volatility		80	%			79	%
	Risk-free interest rate		1.92	%			1.91	%
	Expected lives (years)		6.0				6.0
	Weighted average fair value	$	1.78			$	1.50
Allocation of Stock-Based Compensation Expense by Functional Area
		Year Ended December 31,
	(in thousands)		2014			2013
	Research and development	$	136		$	74
	Sales and marketing		259			163
	General and administrative		742			602
	Total	$	1,137		$	839

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Components Of Deferred Tax Assets (Liabilities)
		Year Ended December 31,
	(in thousands)	2014			2013
	Deferred tax assets:
	Depreciation and amortization	$	7,805		$	8,698
	Other		1,358			1,651
	Net operating losses		58,276			54,005
	Total deferred tax assets		67,439			64,354
	Valuation allowance		-67,431			-64,346
	Net deferred tax assets	$	8		$	8
	Deferred tax liabilities:
	Other	$	-8		$	-8
	Total deferred tax liabilities	$	-8		$	-8
	Net deferred tax asset (liability)	$	-		$	-
Reconciliation Of Statutory Federal Income Tax Rate
		Year Ended December 31,
		2014			2013
	Tax at federal statutory rate	34	%		34	%
	State tax, net of federal benefit	1			2
	Valuation allowance	-16			-39
	Change in warrant valuation	-			-
	Net operating loss and credit reduction due to section 382 limitations	-			-
	Permanent items	-3			-1
	Other	-16			4
	Effective income tax rate	-	%		-	%
Reconciliation Of Change In Unrecognized Tax Benefits
	(in thousands)			Federal Tax			State Tax		Total
	Balance at December 31, 2012		$	5,655		$	5,242	$	10,897
	Increase in tax position during 2012			72			54		126
	Decrease due to expirations			-687			-272		-959
	Balance at December 31, 2013		$	5,040		$	5,024	$	10,064
	Increase in tax position during 2014			148			111		259
	Decrease due to expirations			-			-		-
	Balance at December 31, 2014		$	5,188		$	5,135	$	10,323

Basis_Of_Presentation_And_Sign2

Basis Of Presentation And Significant Accounting And Reporting Policies (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 11, 2015	Dec. 23, 2014	Dec. 23, 2014	13-May-13
	segment
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued	43,115,790	35,825,673
Price per share	$0.00	$0.00
Proceeds from issuance of private placement	$10,288,000	$11,751,000
Warrants outstanding to purchase shares	4,629,018,000	497,359,000
Accumulated deficit	-351,473,000	-332,264,000
License revenue recognized	454,000	454,000
Patent costs	380,000	475,000
Number of reportable segments	1
Subsequent Event [Member] | Quest Diagnostics [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
License revenue recognized			315,518
Private Placement [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued				6,944,445	6,944,445	8,000,000
Price per share				$1.44	$1.44	$1.46
Issued a warrant to purchase common stock with an exercise price				$0.13	$0.13	$0.13
Proceeds from issuance of private placement				10,521,000	10,521,000	13,242,500
Net proceeds from issuance of private placement				$10,281,000	$10,281,000	$11,751,000
Warrants outstanding to purchase shares	4,166,659					12,500,000
Exercise price of warrants	2					1.46
Minimum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Useful life	3 years
Maximum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Useful life	5 years

Strategic_Alliance_And_Secured1

Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated (Details) (USD $)	1 Months Ended	12 Months Ended	0 Months Ended
	Jul. 31, 2005	Dec. 31, 2013	Mar. 11, 2015	Sep. 30, 2009	Dec. 31, 2014
	item
Quest Diagnostic Has Disputed That The Milestone Was Met And The Total Settlement Has Been Made [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility Additional Reduction In Outstanding Principal Balance				$1,000,000
Quest Diagnostics [Member]
Line of Credit Facility [Line Items]
Number of diagnostics tests	3
Quest Diagnostics provided secured line of credit	10,000,000
Line of Credit, reduction in principal amount		3,000,000
Accounts receivable, Quest Diagnostics		373,000			167,000
Quest Diagnostics [Member] | Selected To Commercialize [Member]
Line of Credit Facility [Line Items]
Number of diagnostics tests	2
Subsequent Event [Member] | Quest Diagnostics [Member]
Line of Credit Facility [Line Items]
Total settlement			$1,069,000

Property_And_Equipment_Narrati

Property And Equipment (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property And Equipment [Abstract]
Depreciation expense for property and equipment	$141,000	$72,000

Property_And_Equipment_Compone

Property And Equipment (Components Of Property And Equipment) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Gross property and equipment	$960	$725
Accumulated depreciation and amortization	-452	-334
Property and equipment, net	508	391
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	563	501
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	38	33
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	291	116
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$68	$75

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]
Payroll and benefits related expenses	$905	$548
Collaboration and research agreements expenses	338	187
Professional services	598	262
Tax-related liabilities	23	42
Other accrued liabilities	337	244
Total accrued liabilities	$2,201	$1,283

Commitments_And_Contingencies_

Commitments And Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Commitments And Contingencies [Line Items]
Operating leases rental expense	$130,000		$96,000
Research and development	4,667,000	[1]	2,595,000	[1]
Johns Hopkins University School of Medicine
Commitments And Contingencies [Line Items]
Collaboration support payable	625,000
Research and development	1,323,000		658,000
Percent of royalty paid	4.00%
Minimum royalty payment	57,500
Austin, Texas facility
Commitments And Contingencies [Line Items]
Annual base rent	130,000
Annual estimated common area charges, taxes and insurance	$62,000
[1]	Research and development $136, 76

Common_Stock_Narrative_Details

Common Stock (Narrative) (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 23, 2014	Dec. 23, 2014	Dec. 19, 2013	13-May-13	Oct. 31, 2014
Common Stock Equity [Line Items]
Common stock, shares issued	43,115,790	35,825,673
Price per share	$0.00	$0.00
Proceeds from issuance of private placement	$10,288,000	$11,751,000
Warrants outstanding to purchase shares	4,629,018,000	497,359,000
Common stock value	43,000	36,000
Aggregate proceeds from common stock issued	10,288,000	11,751,000
Value of warrants		17,647,000
Maximum acquisition		2,000,000
Common Stock [Member]
Common Stock Equity [Line Items]
Aggregate proceeds from common stock issued	7,000	8,000
Value of warrants		12,000
Private Placement [Member]
Common Stock Equity [Line Items]
Common stock, shares issued			6,944,445	6,944,445		8,000,000
Price per share			$1.44	$1.44		$1.46
Issued a warrant to purchase common stock with an exercise price			$0.13	$0.13		$0.13
Proceeds from issuance of private placement			10,521,000	10,521,000		13,242,500
Net proceeds from issuance of private placement			10,281,000	10,281,000		11,751,000
Warrants outstanding to purchase shares	4,166,659					12,500,000
Exercise price of warrants	2					1.46
Fair value of warrants issued	2,970,000	9,300,000
Common stock value	7,311,000	3,943,000
Shares of common stock called by warrants upon exercise of warrants					12,087,000
Value of warrants					17,647,000
Other Equity Offerings [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Common stock, shares issued	48,473
Aggregate proceeds from common stock issued	75,000
Net proceeds after deducting offering costs from common stock issued	0
Maximum [Member] | Other Equity Offerings [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Aggregate offering price of common stock							$15,000,000
Commission of gross proceeds from common stock issued							3.00%

Common_Stock_Schedule_Of_Warra

Common Stock (Schedule Of Warrants Outstanding) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Number of Shares Outstanding under Warrant	4,629,018,000	497,359,000
Period 1 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	1-May-12
Expiration Date	30-Apr-14
Exercise Price per Share	3.18
Number of Shares Outstanding under Warrant		21,000
Period 2 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	1-Nov-12
Expiration Date	31-Oct-14
Exercise Price per Share	1.93
Number of Shares Outstanding under Warrant		21,000
Period 3 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	1-May-13
Expiration Date	30-Apr-15
Exercise Price per Share	1.88
Number of Shares Outstanding under Warrant	21,000	21,000
Period 4 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	13-May-13
Expiration Date	13-May-16
Exercise Price per Share	1.46
Number of Shares Outstanding under Warrant	413,359	413,359
Period 5 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	1-Nov-13
Expiration Date	31-Oct-15
Exercise Price per Share	3.89
Number of Shares Outstanding under Warrant	21,000	21,000
Period 6 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	1-May-14
Expiration Date	30-Apr-16
Exercise Price per Share	4.7
Number of Shares Outstanding under Warrant	7,000
Period 7 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	23-Dec-14
Expiration Date	23-Dec-17
Exercise Price per Share	2
Number of Shares Outstanding under Warrant	4,166,659

Loss_Per_Share_Reconciliation_

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Loss Per Share [Abstract]
Net loss-basic	($19,209)	($8,819)
Net loss-diluted	($19,209)	($8,819)
Net loss-basic	36,082,414	20,926,336
Net loss-diluted	36,082,414	20,926,336
Basic Per Share Amount	($0.53)	($0.42)
Diluted Per Share Amount	($0.53)	($0.42)

Loss_Per_Share_Potential_Share

Loss Per Share (Potential Shares Of Common Stock) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	6,340,064	1,946,994
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,711,046	1,447,968
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,629,018	497,359
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		1,667

Employee_Benefits_Plans_Narrat

Employee Benefits Plans (Narrative) (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 12, 2013	Dec. 31, 2012	Feb. 28, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, exercised	178,699	371,348
Stock options, shares of common stock remained outstanding	1,711,046	1,447,968		1,092,374
Total unrecognized compensation cost related to nonvested stock option awards	$1,371,000
Weighted average period over which unrecognized cost expected to be recognized	3 years 11 days
401(k) Plan, percentage for compensation defer	90.00%
401 (k) contributions	0	0
2000 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Stock options, expiration period	10 years
Stock options, exercised	15,000	125,000
Stock options, shares of common stock remained outstanding	57,900
Maximum common stock provides for issuance under stock plan	0
2000 Stock Plan | Statutory Stock Options | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant price, percentage of fair market value of common stock	100.00%
2000 Stock Plan | Nonstatutory Stock Options | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant price, percentage of fair market value of common stock	85.00%
2010 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period	10 years
Stock options, exercised	163,490	246,348
Maximum common stock provides for issuance under stock plan			3,622,983		1,322,983
Additional shares available for issuance			2,300,000
2010 Stock Incentive Plan | Member of Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted share units granted	103,500	160,938
Fair value of restricted share units	$320,000	$334,000

Employee_Benefit_Plans_Activit

Employee Benefit Plans (Activity Related To Shares Available For Grant) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	1,420,441	22,471
Additional shares reserved		2,300,000
Options canceled	1,070,223	-83,058
Reduction in shares reserved	-124,397	-14,150
Options granted	-1,512,000	-810,000
Restricted stock units granted	-128,500	-160,938
Restricted stock units canceled	-11,667
Shares available at End of period	737,434	1,420,441
2000 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options canceled	124,397	-14,150
Reduction in shares reserved	-124,397	-14,150
2010 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	1,420,441	22,471
Additional shares reserved		2,300,000
Options canceled	945,826	-68,908
Options granted	-1,512,000	-810,000
Restricted stock units granted	-128,500	-160,938
Restricted stock units canceled	-11,667
Shares available at End of period	737,434	1,420,441

Employee_Benefit_Plans_Summary

Employee Benefit Plans (Summary Of Stock Option Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Shares
Number of Shares Beginning Balance	1,447,968	1,092,374
Number of Shares Granted	1,512,000	810,000
Number of Shares Exercised	-178,699	-371,348
Number of Shares Canceled	-1,070,223	-83,058
Number of Shares Ending Balance	1,711,046	1,447,968	1,092,374
Number of Shares Shares exercisable	729,094
Number of Shares Shares expected to vest	805,201
Weighted Average Exercise Price
Weighted Average Exercise Price Beginning Balance	$3.36	$4.17
Weighted Average Exercise Price Granted	$2.58	$2.05
Weighted Average Exercise Price Exercised	$1.34	$1.63
Weighted Average Exercise Price Canceled	$3.77	$8.66
Weighted Average Exercise Price Ending Balance	$2.62	$3.36	$4.17
Weighted Average Exercise Price Shares exercisable	$2.95
Weighted Average Exercise Price Shares expected to vest	$2.38
Aggregate Intrinsic Value Beginning Balance	$780	$20
Aggregate Intrinsic Value Ending Balance	178	780	20
Aggregate Intrinsic Value Shares exercisable	72
Aggregate Intrinsic Value Shares expected to vest	$106
Weighted Average Remaining Contractual Term Balance	7 years 9 months 26 days	7 years 11 months 9 days	6 years 2 months 23 days
Weighted Average Remaining Contractual Term Ending Balance	7 years 9 months 26 days	7 years 11 months 9 days	6 years 2 months 23 days
Weighted Average Remaining Contractual Term Shares exercisable	5 years 9 months 11 days
Weighted Average Remaining Contractual Term Shares expected to vest	9 years 4 months 2 days

Employee_Benefit_Plans_Stock_O

Employee Benefit Plans (Stock Options Outstanding And Exercisable) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$0.01
Exercise Price Upper Range	$28.65
Options Outstanding	1,711,046	1,447,968	1,092,374
Weighted Average Exercise Price	$2.62	$3.36	$4.17
Weighted Average Remaining life	7 years 9 months 26 days
Options Exercisable	729,094
Weighted Average Exercise Price	$2.95
Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$0.01
Exercise Price Upper Range	$1.30
Options Outstanding	42,500
Weighted Average Exercise Price	$1.30
Weighted Average Remaining life	9 years 11 months 12 days
Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$1.31
Exercise Price Upper Range	$2.12
Options Outstanding	713,083
Weighted Average Exercise Price	$1.80
Weighted Average Remaining life	6 years 9 months 7 days
Options Exercisable	413,025
Weighted Average Exercise Price	$1.84
Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$2.13
Exercise Price Upper Range	$3.09
Options Outstanding	724,874
Weighted Average Exercise Price	$2.70
Weighted Average Remaining life	8 years 9 months 29 days
Options Exercisable	203,923
Weighted Average Exercise Price	$2.95
Range Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$3.10
Exercise Price Upper Range	$9.92
Options Outstanding	208,003
Weighted Average Exercise Price	$3.50
Weighted Average Remaining life	8 years 1 month 28 days
Options Exercisable	89,560
Weighted Average Exercise Price	$3.66
Range Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$9.93
Exercise Price Upper Range	$28.65
Options Outstanding	22,586
Weighted Average Exercise Price	$20.28
Weighted Average Remaining life	1 year 5 months 5 days
Options Exercisable	22,586
Weighted Average Exercise Price	$20.28

Employee_Benefit_Plans_Fair_Va

Employee Benefit Plans (Fair Value of Options Vested) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Employee Benefit Plans [Abstract]
Total Intrinsic Value of Options Exercised	$55	$291
Total Fair Value of Vested Options	$655	$550

Employee_Benefit_Plans_Assumpt

Employee Benefit Plans (Assumptions Used to Calculate Fair Value Of Options Granted) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Benefit Plans [Abstract]
Dividend yield
Volatility	80.00%	79.00%
Risk-free interest rate	1.92%	1.91%
Expected lives (years)	6 years	6 years
Weighted average fair value	$1.78	$1.50

Employee_Benefit_Plans_Allocat

Employee Benefit Plans (Allocation Of Employee Stock-Based Compensation Expense By Functional Area) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$136	$76
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	259	163
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	776	637
Employee Stock-based Compensation
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,137	839
Employee Stock-based Compensation | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	136	74
Employee Stock-based Compensation | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	259	163
Employee Stock-based Compensation | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$742	$602

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Income tax benefit (expense)
Operating loss, net carryforwards expiration amount	5,000,000
Deferred tax assets, valuation allowance	67,431,000	64,346,000
Increase in deferred tax asset	6,000,000
Gross unrecognized tax benefits	10,323,000	10,064,000	10,897,000
Federal Tax [Member]
Income Taxes [Line Items]
Operating loss, net carryforwards	165,000,000	146,000,000
Gross unrecognized tax benefits	5,188,000	5,040,000	5,655,000
Federal Tax [Member] | Research Carryforward [Member]
Income Taxes [Line Items]
Deferred tax assets, research and development carryforward		5,040,000
Deferred tax assets, research and development additional credits	148,000
State and Local Jurisdiction
Income Taxes [Line Items]
Operating loss, net carryforwards	140,000,000	121,000,000
Gross unrecognized tax benefits	5,135,000	5,024,000	5,242,000
State and Local Jurisdiction | Research Carryforward [Member]
Income Taxes [Line Items]
Deferred tax assets, research and development carryforward		5,024,000
Deferred tax assets, research and development additional credits	$111,000

Income_Taxes_Domestic_And_Fore

Income Taxes (Domestic And Foreign Components Of Loss Before Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
Loss before income taxes	($19,209)	($8,819)

Income_Taxes_Components_Of_Def

Income Taxes (Components Of Deferred Tax Assets (Liabilities)) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Depreciation and amortization	$7,805	$8,698
Other	1,358	1,651
Net operating losses	58,276	54,005
Total deferred tax assets	67,439	64,354
Valuation allowance	-67,431	-64,346
Net deferred tax assets	8	8
Deferred tax liabilities:
Other	-8	-8
Total deferred tax liabilities	-8	-8
Net deferred tax asset (liability)

Income_Taxes_Reconciliation_Of

Income Taxes (Reconciliation Of Statutory Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
Tax at federal statutory rate	34.00%	34.00%
State tax, net of federal benefit	1.00%	2.00%
Valuation allowance	-16.00%	-39.00%
Permanent items	-3.00%	-1.00%
Other	-16.00%	4.00%

Income_Taxes_Reconciliation_Of1

Income Taxes (Reconciliation Of Change In Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Beginning Balance	$10,064	$10,897
Increase in tax position	259	126
Decrease due to expirations		-959
Ending Balance	10,323	10,064
Federal Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,040	5,655
Increase in tax position	148	72
Decrease due to expirations		-687
Ending Balance	5,188	5,040
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Beginning Balance	5,024	5,242
Increase in tax position	111	54
Decrease due to expirations		-272
Ending Balance	$5,135	$5,024

Other_Related_Party_Transactio1

Other Related Party Transactions (Details) (USD $)	9 Months Ended	3 Months Ended	10 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Oct. 23, 2014
Transactions with Third Party [Line Items]
Payments to related party	$340,000
Director [Member]
Transactions with Third Party [Line Items]
Consulting agreement fee per hour		375
Consulting service expenses		22,375
2010 Stock Incentive Plan [Member]
Transactions with Third Party [Line Items]
Restricted shares awarded			15,000
Restricted stock granted, fair value			$31,000